Zhanat Spatayev

Zhanat Spatayev

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
JSJamilya Saparbay
Jamilya Saparbay
MAMels Assykbayev
Mels Assykbayev
SASaitkarim Abdugafarov
Saitkarim Abdugafarov
GZGulnur Zhakhina
Gulnur Zhakhina
ZSZhanat Spatayev
Zhanat Spatayev
GKGulnara Kulkayeva
Gulnara Kulkayeva
Sensitization to human leukocyte antigens (HLA) antigens is the main obstacle to getting the kidney either from a living or deceased donor. HLA sensitization occurs as the result of repeated pregnancy, blood transfusion, or previous transplantation. Overcoming the HLA incompatibility is one of the approaches to decrease the organ shortage. There are 3.5 % highly sensitized patients among 3012 patients on the waiting list for kidney transplantation in Kazakhstan. In this review, we have discussed most common approaches of desensitization for HS kidney recipients. Huge progress has been made in the field of desensitization in transplant medicine worldwide. We suppose, that implementation the desensitization protocols in clinical guidelines will improve patient survival and outcome after kidney transplantation.

20 January 2025 in Clinical Transplantation and Research
Verified
Journal Article
Open access
PDF file
JSJamilya Saparbay
Jamilya Saparbay
ASAbylaikhan Sharmenov
Abylaikhan Sharmenov
AZAssylmurat Zhumukov
Assylmurat Zhumukov
ARArina Razmazina
Arina Razmazina
CAChokhan Aytbayev
Chokhan Aytbayev
AMAdilbek Mukazhanov
Adilbek Mukazhanov
Jamilya Saparbay, Abylaikhan Sharmenov, Assylmurat Zhumukov, Arina Razmazina, Chokhan Aytbayev, Zhanat Spatayev, Adilbek Mukazhanov. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.24.0050

4 April 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
AСAytbayev Сhokhan
Aytbayev Сhokhan
JSJamilya Saparbay
Jamilya Saparbay
ZAZhumukov Assylmurat
Zhumukov Assylmurat
ASAbylaikhan Sharmenov
Abylaikhan Sharmenov
ZSZhanat Spatayev
Zhanat Spatayev
ZBZhandos Burkitbayev
Zhandos Burkitbayev
Whipple procedure is a most common performed surgery in patients with benign and malignant tumors of pancreas and periampullary region. There is a scarce of data regarding Whipple procedure outcomes in Kazakhstan. The aim of this study was to analyze Whipple procedure outcomes.All Whipple procedures,performed between 2019 and 2023 in National Research Oncology Center, Astana.Data regarding patients were retrieved from electronic records. 97 patients underwent Whipple procedure for malignant tumor. POPF was the most frequent complication after PD. The 1,2,3-year survivals were 83 %,65 % and 48 % respectively. Median survival after Whipple procedure in our study was 20.5 month (95 % CI 18.2-24.0). Surgery remains the only curative treatment method for patients with pancreatic cancer. POPF occurrence was the most common complication and was higher in comparison to other studies. Our findings demonstrate that the modified Blumgart and Dunk anastomosis with duct-to-mucosa suturing significantly reduce the occurrence of postoperative pancreatic fistula. It can be concluded that first 4 year of experience showed comparable learning curve and further improvement in surgical technique and patient selection can decrease morbidity and mortality rate after pancreatoduodenectomy.

JSJamilya Saparbay
Jamilya Saparbay
ZSZhanat Spatayev
Zhanat Spatayev
ASAbylaikhan Sharmenov
Abylaikhan Sharmenov
AZAssylmurat Zhumukov
Assylmurat Zhumukov
CAChokhan Aytbayev
Chokhan Aytbayev
AZAssan Zhexembayev
Assan Zhexembayev
Background: Kazakhstan is among the most highly endemic countries for hepatic echinococcosis worldwide, yet no study systematically characterised the national hepatobiliary surgical burden of cystic (CE) and alveolar (AE) echinococcosis using administrative health data. Methods: National operative data from the Guaranteed Volume of Free Medical Care (GOBMP) and Compulsory Social Health Insurance (OSHI) Systems (1 January 2023–31 December 2025) were combined with institutional case series from the National Research Oncology Center (NROC), Astana (2021–2025). Cases were identified using ICD-10 diagnosis codes and ICD-9-CM procedure codes. Regional and species-specific differences in surgical approach were assessed using Pearson’s chi-square test; continuous variables were compared using the Mann–Whitney U test. Results: A total of 143 hepatic echinococcosis surgeries were performed nationally over the three-year period, with a 12.8% increase in annual volume (47 in 2023, 43 in 2024, 53 in 2025), though this year-to-year variation was not statistically significant (χ2 = 1.06, df = 2, p = 0.59). CE accounted for 74.8% of cases (n = 107), AE for 18.9% (n = 27), and unspecified hepatic echinococcosis for 6.3% (n = 9); the proportion of AE rose from 17.0% in 2023 to 26.4% in 2025. Astana performed 46.2% of all operations nationally, with its share increasing from 34.0% to 58.5% over the study period; together with Almaty, it accounted for 92.6% of all AE cases. Partial hepatic resection was the predominant procedure overall (81.1%), while AE was managed exclusively by resectional or lobar procedures (χ2 = 15.37, p = 0.004), with no percutaneous approaches used. In the NROC case series (n = 63), AE patients were older (median 43.5 vs. 33 years, p = 0.036) and had longer postoperative hospital stays (median 12 vs. 10 days, p = 0.015) than CE patients. Conclusions: Surgical management of hepatic echinococcosis in Kazakhstan is increasingly centralised in Astana and Almaty, with AE consistently requiring more extensive resectional surgery and greater healthcare resource use than CE. These findings support the development of a national echinococcosis registry and formal referral pathways to guide resource allocation and surgical planning.

31 March 2026 in Annals of Transplantation
Verified
Journal Article
Open access
JSJamilya Saparbay
Jamilya Saparbay
ASAbylaikhan Sharmenov
Abylaikhan Sharmenov
CAChokhan Aytbayev
Chokhan Aytbayev
AZAssylmurat Zhumukov
Assylmurat Zhumukov
BYBekkhozha Yeskendirov
Bekkhozha Yeskendirov
ZBZhandos Burkitbayev
Zhandos Burkitbayev
BACKGROUND Liver transplantation (LT) is the definitive treatment for selected patients with end-stage liver disease (ESLD), yet postoperative complications remain a major challenge, particularly in regions where living donor liver transplantation (LDLT) predominates. This study aimed to evaluate surgical outcomes, identify predictors of early mortality, and assess the incidence and impact of biliary complications in a low-volume transplant center in Central Asia. MATERIAL AND METHODS We retrospectively analyzed 113 liver transplantations performed at the National Research Oncology Center between 2013 and 2025. The cohort comprised 88 LDLT (77.9%) and 25 deceased donor LT (DDLT) cases, with a mean recipient age of 43.8 years. RESULTS The overall 1-, 3-, 5-, 7-, and 10-year survival rates were 76.3%, 72.9%, 70.0%, 70.0%, and 70.0%, respectively, with no significant difference between LDLT and DDLT. Biliary leakage (BL) and biliary stricture (BS) occurred in 26.5% and 20% of recipients, respectively. Graft steatosis and external bile duct (EBD) stenting were independent predictors of BL, while intraoperative bleeding and EBD predicted BS. Hepatic artery thrombosis (HAT) occurred in 14.1% of patients and was a significant predictor of 90-day mortality. Sepsis was the strongest predictor of 30-day (OR 7.92, P=0.022) and 90-day mortality (OR 20.1, P CONCLUSIONS Biliary complications remain common, particularly in LDLT, and are influenced by graft and reconstruction factors. Advances in surgical technique, infection control, and early recognition of vascular complication remain decisive for optimizing outcomes after liver transplantation.

7 January 2026 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Open access
PDF file
LNLyazzat Bekenkyzy Nur
Lyazzat Bekenkyzy Nur
MMMarzhan Marzhan
Marzhan Marzhan
AAAibar Aginbay
Aibar Aginbay
KKKulpash Kaliaskarova
Kulpash Kaliaskarova
ZSZhanat Spatayev
Zhanat Spatayev
BKBairam Kochiyev
Bairam Kochiyev
Posterior reversible encephalopathy syndrome (PRES) is a neurological condition characterized by seizures, encephalopathy, visual disturbances, and headache, often occurring in the context of hypertension and immunosuppressive therapy after solid organ transplantation. Although classically presenting with vasogenic edema in the parieto-occipital regions, atypical patterns may also occur. Here we report our experience with a case of cyclosporine-related PRES after liver transplant and summarize PRES clinical features through a literature review. The case was a 53-year-old man who received a deceased donor liver transplant. His initial immunosuppressive therapy comprised cyclosporine/mycophenolate mofetil/prednisolone. Five months after transplantation, he was admitted to our center with altered mental status. The patient was diagnosed with PRES based on neurological symptoms and neuroimaging findings and recovered after switching from cyclosporine to everolimus. In addition, the lowering of blood pressure with drugs reported in the literature for use in PRES proved to be effective but challenging, requiring the use of multiple agents and only slowly leading to adequate control of hypertensive peaks. Nonetheless, hypertension management and supportive therapy allowed for a complete neurological recovery of the patient. In conclusion, cyclosporine-associated PRES has a generally favorable prognosis with early diagnosis and prompt treatment, including altering or discontinuing CNIs and controlling blood pressure. CNI-associated PRES should be considered in patients exhibiting acute neurological symptoms after transplantation. Early diagnosis and immediate treatment are critical for a favorable prognosis.